Carregant...
Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
BACKGROUND: Therapeutic drug monitoring may optimize therapy for Crohn's disease (CD). AIM: To use a population pharmacokinetic model that accounts for the time‐varying nature of covariates to simulate certolizumab pegol (CZP) concentrations to evaluate the exposure‐response relationship for CZ...
Guardat en:
| Publicat a: | Aliment Pharmacol Ther |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5765392/ https://ncbi.nlm.nih.gov/pubmed/29159893 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.14421 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|